However, in luminal BC cells, RUNX2 did not promote the loss of E-Cadherin, the downregulation of ER or the expression of N-Cadherin and Vimentin, which are indicative of an EMT progression (Supplementary Figure S1D). This evidence concerns the gene RUNX2 and breast cancer.